GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genomic Vision SA (LTS:0QT4) » Definitions » Capex-to-Operating-Cash-Flow

Genomic Vision (LTS:0QT4) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Genomic Vision Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Genomic Vision's Capital Expenditure for the six months ended in Jun. 2023 was €0.00 Mil. Its Cash Flow from Operations for the six months ended in Jun. 2023 was €-2.69 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Genomic Vision Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Genomic Vision's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Vision Capex-to-Operating-Cash-Flow Chart

Genomic Vision Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genomic Vision Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genomic Vision's Capex-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, Genomic Vision's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomic Vision's Capex-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genomic Vision's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Genomic Vision's Capex-to-Operating-Cash-Flow falls into.



Genomic Vision Capex-to-Operating-Cash-Flow Calculation

Genomic Vision's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.102) / -4.41
=N/A

Genomic Vision's Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -2.69
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genomic Vision  (LTS:0QT4) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Genomic Vision Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Genomic Vision's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomic Vision (LTS:0QT4) Business Description

Traded in Other Exchanges
N/A
Address
80-84 rue des Meuniers, Green Square, Batiment E, Bagneux, FRA, 92220
Genomic Vision SA is a molecular diagnostics and technology company specialized in the development of single DNA detection tools for research and in vitro diagnostics.

Genomic Vision (LTS:0QT4) Headlines

No Headlines